Clinical trial researching therapy for RUNX1 mutations

Patient with doctor

Image credit: Canva

The runt-related transcription factor 1 (RUNX1) gene regulates the formation of blood cells. People with mutations in the gene are at risk of bleeding and have a higher risk of developing cancers of the blood. A clinical trial led by Lea C. Cunningham, M.D., Associate Research Physician in the Immune Deficiency Cellular Therapy Program, is researching a drug for RUNX1 mutations.

The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.

For more information, please contact Rebecca Alexander at (240) 781-4037 or identifier: NCT06090669

NCI Protocol ID: IRB001542

Official Title: Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland. 

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Posted on Tue, 01/30/2024